1. Edaravone acts as a potential therapeutic drug against pentylenetetrazole-induced epilepsy in male albino rats by downregulating cyclooxygenase-II.
- Author
-
Liu LM, Wang N, Lu Y, and Wang WP
- Subjects
- Animals, Antioxidants pharmacology, Brain drug effects, Brain metabolism, Convulsants pharmacology, Disease Models, Animal, Down-Regulation, Gene Expression Profiling, Male, Neuroprotective Agents pharmacology, Nitric Oxide metabolism, Pentylenetetrazole pharmacology, Rats, Rats, Wistar, Treatment Outcome, Cyclooxygenase 2 genetics, Cyclooxygenase 2 metabolism, Edaravone pharmacology, Epilepsy drug therapy, Epilepsy etiology
- Abstract
Introduction: The effects of edaravone against pentylenetetrazole (PTZ)-induced epilepsy in male albino rats were investigated. Edaravone is a well-known commercial drug used in the treatment of strokes and amyotrophic lateral sclerosis (ALS). Antioxidant and free radical scavenging activities of edaravone have been reported in patients with ALS., Methods: In this study, the experimental groups were as follows: sham, control, 5 mg/kg edaravone, and 10 mg/kg edaravone. Behavioral assessment, determination of biochemical markers, apoptosis, nitric oxide (NO), and mRNA and protein expression of cyclooxygenase-II (COX-II) were carried out. Seizure incidence, including generalized tonic-clonic seizure (GTCS) and minimal clonic seizure (MCS), was directly associated with PTZ administration in rats., Results: Edaravone supplementation substantially increased MCS and GTCS latency in rats, and biochemical markers were significantly altered in the brain tissue of PTZ-treated rats. Edaravone treatment normalized altered biochemical markers compared with the untreated control. Apoptosis and NO levels were significantly reduced by more than 50% compared to their respective controls. COX-II mRNA was increased by 130% in PTZ-treated rats, while edaravone supplementation reduced mRNA and protein expression of COX-II by more than 20% and 40%, respectively. Immunohistochemistry indicated that COX-II protein expression was reduced by 13.2% and 33.7% following supplementation with 5 and 10 mg/kg edaravone, respectively., Conclusion: Taken together, our results suggest that edaravone functions by downregulating the levels of COX-II and NO and is a potential candidate for the treatment of PTZ-induced epilepsy., (© 2018 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF